$2.03 Billion is the total value of Weiss Multi-Strategy Advisers LLC's 398 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MDC | MDC HOLDINGSput | $3,015,000 | -0.6% | 117,500 | 0.0% | 0.15% | -21.9% | |
| CZR | CAESARS ENTER STKcall | $2,975,000 | +14.1% | 350,000 | 0.0% | 0.14% | -10.6% | |
| EVA | ENVIVA PARTNERS LP | $2,010,000 | -0.7% | 75,000 | 0.0% | 0.10% | -21.6% | |
| KTWO | K2M GROUP HOLDINGS INC | $1,784,000 | +12.8% | 89,000 | 0.0% | 0.09% | -11.2% | |
| HCHC | HC2 HOLDINGS INC | $1,779,000 | +8.8% | 300,000 | 0.0% | 0.09% | -14.9% | |
| FPRX | FIVEPRIME THERAPEUTICS INC | $1,403,000 | -4.6% | 28,000 | 0.0% | 0.07% | -25.3% | |
| ARRY | ARRAY BIOPHARMA STK | $1,187,000 | +30.3% | 135,000 | 0.0% | 0.06% | +3.6% | |
| IDXX | IDEXX LABS | $850,000 | +4.0% | 7,251 | 0.0% | 0.04% | -18.0% | |
| ATRC | ATRICURE INC | $734,000 | +23.8% | 37,500 | 0.0% | 0.04% | -2.7% | |
| NSTG | NANOSTRING TECHNOLOGIES INC | $714,000 | +11.7% | 32,000 | 0.0% | 0.04% | -10.3% | |
| SYRS | SYROS PHARMACEUTICALS INC | $596,000 | -12.4% | 49,000 | 0.0% | 0.03% | -31.0% | |
| IONS | IONIS PHARMACEUTICALS INC | $478,000 | +30.6% | 10,000 | 0.0% | 0.02% | 0.0% | |
| PETX | ARATANA THERAPEUTICS INC | $431,000 | -23.3% | 60,000 | 0.0% | 0.02% | -40.0% | |
| PACB | PACIFIC BIOSCIENCES OF CALIF | $407,000 | -57.6% | 107,000 | 0.0% | 0.02% | -66.1% | |
| CRIS | CURIS STK | $382,000 | +17.9% | 124,000 | 0.0% | 0.02% | -5.0% | |
| KERX | KERYX BIOPHARMA STK | $375,000 | +10.3% | 64,000 | 0.0% | 0.02% | -14.3% | |
| AGEN | AGENUS INC | $375,000 | -42.6% | 91,000 | 0.0% | 0.02% | -55.0% | |
| ALDX | ALDEYRA THERAPEUTICS INC | $348,000 | -31.5% | 65,000 | 0.0% | 0.02% | -45.2% | |
| WMGI | WRIGHT MEDICAL GROUP NV | $322,000 | -6.1% | 14,000 | 0.0% | 0.02% | -23.8% | |
| ADXS | ADVAXIS INC | $286,000 | -33.2% | 40,000 | 0.0% | 0.01% | -46.2% | |
| SGMO | SANGAMO BIOSCIENCES INC | $259,000 | -34.3% | 85,000 | 0.0% | 0.01% | -45.8% | |
| XENE | XENON PHARMACEUTICALS INC | $243,000 | -4.7% | 31,500 | 0.0% | 0.01% | -25.0% | |
| NVS | NOVARTIS ADR | $255,000 | -7.6% | 3,500 | 0.0% | 0.01% | -29.4% | |
| SPNC | SPECTRANETICS CORP C | $245,000 | -2.4% | 10,000 | 0.0% | 0.01% | -20.0% | |
| OCRX | OCERA THERAPEUTICS INC | $231,000 | -20.3% | 110,000 | 0.0% | 0.01% | -38.9% | |
| ICPT | INTERCEPT PHARMACEUTICALS IN | $217,000 | -34.0% | 2,000 | 0.0% | 0.01% | -45.0% | |
| DGAZ | VELOCITYSHARES 3X INVERSE NA | $212,000 | -50.2% | 70,000 | 0.0% | 0.01% | -61.5% | |
| INSYQ | INSYS THERAPEUTICS INC | $193,000 | -22.2% | 21,000 | 0.0% | 0.01% | -40.0% | |
| TGTX | TG THERAPEUTICS INC | $140,000 | -39.7% | 30,000 | 0.0% | 0.01% | -50.0% | |
| TTOO | T2 BIOSYSTEMS INC | $132,000 | -27.1% | 25,000 | 0.0% | 0.01% | -45.5% | |
| ALIM | ALIMERA SCIENCES INC | $92,000 | -27.6% | 85,000 | 0.0% | 0.00% | -50.0% | |
| CERS | CERUS CORP COM | $87,000 | -29.8% | 20,000 | 0.0% | 0.00% | -50.0% | |
| CPRX | CATALYST PHARMACEUTICALS PAR | $71,000 | -4.1% | 68,000 | 0.0% | 0.00% | -40.0% | |
| ONTX | ONCONOVA THERAPEUTICS INC | $55,000 | -14.1% | 24,087 | 0.0% | 0.00% | -25.0% | |
| ANTH | ANTHERA PHARMACEUTICALS INC | $38,000 | -79.3% | 58,500 | 0.0% | 0.00% | -81.8% | |
| GERN | GERON CORP | $41,000 | -8.9% | 20,000 | 0.0% | 0.00% | -33.3% | |
| FOLD | AMICUS THERAPEUTICS INC | $50,000 | -32.4% | 10,000 | 0.0% | 0.00% | -60.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| DEXCOM INC | 42 | Q3 2023 | 0.4% |
| EDWARDS LIFESCIENCE CORPORAT | 42 | Q3 2023 | 0.3% |
| MERCK & CO | 42 | Q3 2023 | 0.4% |
| BIOMARIN PHARMACEUTICAL | 42 | Q3 2023 | 0.4% |
| VERTEX PHARMACEUTICA | 41 | Q3 2023 | 0.5% |
| RIGEL PHARMACEUTICALS INC | 41 | Q3 2023 | 0.1% |
| BOSTON SCIENTIFIC | 40 | Q3 2023 | 0.4% |
| PACIFIC BIOSCIENCES OF CALIF | 40 | Q3 2023 | 0.5% |
| ASTRAZENECA PLC-SPONS ADR | 39 | Q3 2023 | 0.3% |
| ABIOMED INC | 38 | Q3 2022 | 0.3% |
View Weiss Multi-Strategy Advisers LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| COMSCORE, INC. | February 14, 2023 | 9,022,812 | 9.8% |
| NETSTREIT Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| RPT RealtySold out | February 14, 2022 | 0 | 0.0% |
| Tiberius Acquisition Corp | February 12, 2019 | 1,327,700 | 6.2% |
| Ashford Hospitality Prime, Inc. | February 14, 2017 | 1,183,378 | 4.6% |
| Community Bankers Trust Corp | February 12, 2014 | 500,000 | 2.3% |
| Crumbs Bake Shop, Inc.Sold out | February 12, 2013 | 0 | 0.0% |
| WESTERN LIBERTY BANCORP | February 13, 2012 | 1,165,817 | 8.1% |
| 57th Street General Acquisition Corp | February 11, 2011 | 350,000 | 5.8% |
| CENTERLINE HOLDING CO | February 11, 2011 | 2,759,200 | 0.8% |
View Weiss Multi-Strategy Advisers LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-04-12 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
View Weiss Multi-Strategy Advisers LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.